Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Shares Issued (2020 - 2023)

Maravai Lifesciences Holdings (MRVI) has 4 years of Shares Issued data on record, last reported at $312000.0 in Q3 2023.

  • For Q3 2023, Shares Issued fell 57.26% year-over-year to $312000.0; the TTM value through Sep 2023 reached $1.9 million, down 18.08%, while the annual FY2022 figure was $2.4 million, 37.98% up from the prior year.
  • Shares Issued reached $312000.0 in Q3 2023 per MRVI's latest filing, down from $365000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $730000.0 in Q3 2022 and bottomed at $311000.0 in Q3 2021.
  • Average Shares Issued over 4 years is $470000.0, with a median of $414000.0 recorded in 2021.
  • Peak YoY movement for Shares Issued: soared 134.73% in 2022, then crashed 57.26% in 2023.
  • A 4-year view of Shares Issued shows it stood at $321000.0 in 2020, then grew by 18.38% to $380000.0 in 2021, then decreased by 3.95% to $365000.0 in 2022, then dropped by 14.52% to $312000.0 in 2023.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $312000.0 in Q3 2023, $365000.0 in Q4 2022, and $730000.0 in Q3 2022.